Results

Total Results: 80 records

Showing results for "psa".
Users also searched for: aspirin

1. PCA3 Testing for the Diagnosis and Management of Prostate Cancer | Effective Health Care (EHC) Program
   effectivehealthcare-admin.ahrq.gov/products/prostate-cancer-test/research-protocol
   December 01, 2019 - values, decreased percent-free PSA levels, elevated PSA velocities, complexed PSA, or externally validated … values, decreased percent-free PSA levels, elevated PSA velocities, complexed PSA, or externally validated … PCA3 comparators Total PSA Percent free PSA PSA velocity Complexed PSA Externally validated … , percent free PSA, PSA velocity, complexed PSA, externally validated nomograms) KQ3: No PCA3 testing … , % free PSA, PSA velocity, complexed PSA, or externally validated nomograms) in predicting initial or

2. Arthritis-Psoriatric Executive (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_executive.pdf
   April 01, 2012 - Psoriatic Arthritis in Adults: Update of a 2007 Report Executive Summary Background Psoriatic arthritis (PsA … PsA has a highly variable presentation, which generally involves pain and inflammation in joints and … In the general population, the prevalence of PsA is estimated to be 0.3 percent to 1 percent. … Census, 520,000 people ages 18 or older in the United States have PsA. … However the current available evidence for PsA was limited.

3. Effective Health Care (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/TND_0332_07-29-2010.pdf
   January 01, 2010 - in comparing results of screening with PCA3 with results of traditional prostate specific antigen (PSA … Transcription-mediated amplification of PCA3 and PSA mRNA in urine sample b. … How does sensitivity and specificity vary by score (ratio of PCA3/PSA mRMA) cut-off? b. … How do these issues vary as a function of PSA result and biopsy status? 4. … Reduction in unnecessary initial biopsies resulting from false positive PSA results ii.

4. Prostate-Cancer-Test Research-Protocol (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/prostate-cancer-test_research-protocol.pdf
   October 14, 2011 - values, decreased percent-free PSA levels, elevated PSA velocities, complexed PSA, or externally validated … values, decreased percent- free PSA levels, elevated PSA velocities, complexed PSA, or externally validated …  PCA3 comparators ○ Total PSA ○ Percent free PSA ○ PSA velocity ○ Complexed PSA ○ Externally … , percent free PSA, PSA velocity, complexed PSA, externally validated nomograms) KQ3: No PCA3 testing … , % free PSA, PSA velocity, complexed PSA, or externally validated nomograms) in predicting initial

5. Therapies for Clinically Localized Prostate Cancer: Evidence Summary (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/prostate-cancer-therapies-summary.pdf
   September 01, 2020 - clinically localized prostate cancer (CLPC) detected clinically rather than by prostate-specific antigen (PSA … to no mortality difference versus RP or external beam radiation (EBR)+androgen deprivation (AD) in PSA … ProtecT PSA-based active monitoring group is labeled active surveillance in figure. … Absolute effects are likely smaller among PSA-detected CLPC due to its more indolent course. … AM was compared with RP or EBR plus AD in PSA screen–detected CLPC.

6. Layout 1 (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer_executive.pdf
   February 01, 2008 - We focused on baseline PSA levels and Gleason histologic score. … Prostate cancers not detected by PSA testing. … with PSA levels and rate of PSA rise … levels in men with PSA-detected disease. … PSA testing.

7. 04-E029-1 Summary (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer-surveillance_executive.pdf
   December 01, 2011 - Two cohorts used PSA density (PSA per volume of prostate tissue) thresholds. … All seven cohorts in the PSA screening era included regular PSA testing. … screening era reported that PSA testing became part of followup protocol after PSA became available. … All six cohorts in the PSA screening era included regular PSA testing as part of followup protocol. … at diagnosis, decreased free-to-total PSA ratio, or more rapid PSA increase, but not comorbidities or

8. Disposition of Comments for PCA3 Testing for the Diagnosis and Management of Prostate Cancer (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer-test_disposition-comments.pdf
   April 01, 2013 - Current AUA guidelines for PSA screening recommend another serum PSA when presented with an abnormal … values (PSA velocity) if available, free PSA if available, family history, race, etc. are considered … It is likely that tPSA and PSA density are correlated because tPSA is used in the calculation of PSA … serum PSA, this approach introduces the following issues: 1) PSA is used differently for repeat … PSA data.

9. Psoriatic Arthritis Surveillance Assesment_CER 54_Low (pdf file)
   effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/arthritis-psoriatric_surveillance.pdf
   March 01, 2013 - Thus, 14 articles were reviewed for PsA. … A new meta-analysis9 found PsA Response Criteria (PsARC) response at 12-14 weeks was significantly … This drug is not approved for PsA. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date. … This drug is not approved for PsA. EPC Investigator felt the conclusions were up to date.

10. Prostate-Cancer-Therapies-Update Executive (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/prostate-cancer-therapies-update_executive.pdf
    December 01, 2014 - Comparative Effectiveness Review Number 146 a physical examination, prostate-specific antigen (PSA … Effective Health Care Program 2 The PSA test is used to measure blood levels of PSA, a protein produced … separating a “normal” PSA level from an abnormal level also remains a subject of debate. … PSA, PSA kinetics (rate of rise in PSA over time and doubling time for PSA), and digital rectal examination … cancer (especially low PSA/low-risk disease, but possibly intermediate PSA/intermediate-risk disease

11. Therapies for Clinically Localized Prostate Cancer | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/prostate-cancer-therapies/report
    January 01, 2021 - to no mortality difference versus RP or external beam radiation (EBR)+androgen deprivation (AD) in PSA … Among clinically rather than prostate-specific antigen (PSA) detected CLPC, Watchful Waiting (WW) may … effect on mortality may vary by tumor risk and age but not by race, health status, comorbidities, or PSA … Active Monitoring (AM) probably results in little to no difference in mortality in PSA-detected CLPC … RCTs in PSA-detected and MRI staged CLPC are needed.

12. PCA3 Testing for the Diagnosis and Management of Prostate Cancer | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/prostate-cancer-test/research
    December 01, 2019 - Comparators included total prostate specific antigen (PSA) elevations, free PSA, PSA density, PSA velocity … , externally validated nomograms, complexed PSA, and multivariate models. … Comparison of PCA3 to total PSA (tPSA) had the most available studies (22) but was subject to spectrum

13. Comparative Effectiveness of Therapies for Clinically Localized Prostate Cancer: An Update of a 2008 Comparative Effectiveness Review | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/prostate-cancer-therapies-update/research-protocol
    December 01, 2019 - The PSA test is used to measure blood levels of PSA, a protein produced by the prostate gland. 4 Elevated … ≤6   T1–2a N0 M0 PSA X Gleason X IIA T1a–c N0 M0 PSA<20 Gleason 7 …   T1a–c N0 M0 PSA≥10<20 Gleason ≤6   T2a N0 M0 PSA≥10<20 Gleason ≤6 …   T2a N0 M0 PSA<20 Gleason 7   T2b N0 M0 PSA<20 Gleason ≤7 IIB T2b … N0 M0 PSA X Gleason X   T2c N0 M0 Any PSA Any Gleason   T1–2 N0

14. Prostate-Cancer-Therapies-Update Consumer (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/prostate-cancer-therapies-update_consumer.pdf
    January 01, 2016 - � PSA blood test: This blood test tells how much PSA (a protein made by the prostate gland) is in … – A high PSA level does not always mean a man has prostate cancer. … This growth, and other health conditions, can cause a high PSA level in men who do not have prostate … Your doctor can use your PSA level, Gleason score, and tumor score (T-score) to determine your risk … The cancer is found from a biopsy done after a man has a high PSA level or has surgery for problems

15. Tx-For-Localized-Prostate-Cancer Surveillanceassesment 20120614 (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/tx-for-localized-prostate-cancer_surveillanceassesment_20120614.pdf
    May 01, 2012 - However, a subgroup analysis suggested that men with high-risk features (PSA > 10, and intermediate … levels and Gleason histologic score (PSA >10 ng/ml or Gleason >6). … In men with PSA >10, radical prostatectomy reduced overall mortality (HR = 0.36, p=0.03). … In men with PSA >10, radical prostatectomy reduced overall mortality (HR = 0.36, p=0.03). … levels and Gleason histologic score (PSA >10 ng/ml or Gleason >6).

16. Tx-For-Localized-Prostate-Cancer Surveillanceassesment 20120614 (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/tx-for-localized-prostate-cancer_surveillanceassesment_20120614.pdf
    May 01, 2012 - However, a subgroup analysis suggested that men with high-risk features (PSA > 10, and intermediate … levels and Gleason histologic score (PSA >10 ng/ml or Gleason >6). … In men with PSA >10, radical prostatectomy reduced overall mortality (HR = 0.36, p=0.03). … In men with PSA >10, radical prostatectomy reduced overall mortality (HR = 0.36, p=0.03). … levels and Gleason histologic score (PSA >10 ng/ml or Gleason >6).

17. Therapies for Clinically Localized Prostate Cancer (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/prostate-cancer-therapies-update_clinician.pdf
    January 01, 2016 - convened in 2011 recommended that AS—a strategy with curative intent that involves regular monitoring of PSA … and then intervening to manage them.3 WW does not include active monitoring such as performing a PSA … Presenting symptoms, a physical examination, a prostate- specific antigen (PSA) test, and a biopsy may … by factors such as patient age and health at the time of diagnosis, life expectancy, tumor stage, PSA … Prostate cancer incidence and PSA testing patterns in relation to USPSTF screening recommendations.

18. Prostate-Cancer-Therapies-Update Research-Protocol (pdf file)
    effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/prostate-cancer-therapies-update_research-protocol.pdf
    April 01, 2013 - The PSA test is used to measure blood levels of PSA, a protein produced by the prostate gland.4 Elevated … Anatomic and prognostic staging Stage Group T* N M PSA Gleason I T1a–c N0 M0 PSA<10 Gleason ≤6 T2a … N0 M0 PSA<10 Gleason ≤6 T1–2a N0 M0 PSA X Gleason X IIA T1a–c N0 M0 PSA<20 Gleason 7 T1a–c N0 M0 … PSA≥10<20 Gleason ≤6 T2a N0 M0 PSA≥10<20 Gleason ≤6 T2a N0 M0 PSA<20 Gleason 7 T2b N0 M0 PSA<20 … Gleason ≤7 IIB T2b N0 M0 PSA X Gleason X T2c N0 M0 Any PSA Any Gleason T1–2 N0 M0 PSA≥20 Any Gleason

19. Comparative Effectiveness of Drug Therapy for Psoriatic Arthritis in Adults – An Update to the 2007 Report | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/arthritis-psoriatric/research-protocol
    December 01, 2019 - PsA has a highly variable presentation, which generally involves pain and inflammation in joints and … Additionally, PsA may predate the development of skin disease leading to some diagnostic uncertainty. … In the general population the prevalence of PsA is estimated to be 0.3% to 1%. … Treatment of psoriatic arthritis (PsA) aims to control pain and inflammation and, ultimately, to slow … The oral DMARDs used to treat patients with PsA are hydrochloroquine, leflunomide, methotrexate, and

20. Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report | Effective Health Care (EHC) Program
    effectivehealthcare-admin.ahrq.gov/products/arthritis-psoriatric/research
    December 01, 2019 - oral and biologic disease-modifying antirheumatic drugs (DMARDs) for adults with psoriatic arthritis (PsA … controlled trials meeting inclusion criteria existed for any drugs in this review for treating patients with PsA … evidence supported the efficacy of adalimumab, etanercept, golimumab, and infliximab for the treatment of PsA … conclusions on comparative efficacy, effectiveness, and harms of either oral or biologic DMARDs for PsA … therapy to prevent or minimize debilitating joint damage and optimize quality of life for people with PsA